Which diabetes pill is better for Early-Stage patients? major trial compares dapagliflozin and metformin

NCT ID NCT03982381

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two common diabetes drugs—dapagliflozin and metformin—in over 2,000 people with early type 2 diabetes (diagnosed less than 4 years). The goal was to see which drug better prevents serious complications like death, heart attack, stroke, heart failure, kidney disease, eye problems, and foot ulcers. Participants took either dapagliflozin or metformin, and researchers tracked their health using national registries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dapagliflozin (a drug that lowers blood sugar by helping the kidneys remove sugar through urine)
What this could lead to
If dapagliflozin works better than metformin, it could become a preferred first treatment for early type 2 diabetes to reduce the risk of serious complications like heart attack, stroke, and kidney disease.
What could go wrong
This is a completed Phase 4 trial, but it is open-label (patients and doctors know the treatment), which can bias results. Also, the benefit may be small or not apply to all patients with early diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Uppsala University Hospital

    Uppsala, 75185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.